Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
18 Results for "
Metabolic Dysfunction-Associated Steatotic Liver Disease
" in MedChemExpress (MCE) Product Catalog:
Products (18)
18 Results for "Metabolic Dysfunction-Associated Steatotic Liver Disease" in MCE Product Catalog:
2
2 Cited Publications
Research Areas:
DI-1859 is a DCN1 and cullin 3 inhibitor with a Ki of <1 nM against human DCN1. DI-1859 forms a covalent bond with Cys115 of DCN1, cleaves its dimethylamino group, disrupts the DCN1-UBC12 interaction, and selectively inhibits the neddylation modification of cullin 3 relative to other cullins. DI-1859 inactivates CRL3, promotes the accumulation of NRF2 and SLC7A11, upregulates the expression of HO-1 and NQO1, reduces reactive oxygen species (ROS) levels, enhances insulin signaling, promotes insulin secretion, activates RhoA, regulates the phosphorylation of AKT, without completely blocking the neddylation modification of cullin 3 or restoring the expression of IRS-1. DI-1859 can be used in the research of Acetaminophen (HY-66005)-induced hepatotoxicity, hyperglycemia, metabolic dysfunction-associated steatotic liver disease, insulin resistance, breast cancer and lung cancer .
1
1 Cited Publications
Cat. No.: HY-N0732
CAS No.: 37905-08-1
Cat. No.: HY-P11274A
Synonyms: Amycretin sodium; NN 9487 sodium
Target:
Research Areas:
Cat. No.: HY-P11274
CAS No.: 3005889-81-3
Synonyms: Amycretin; NN 9487
Target:
Research Areas:
Cat. No.: HY-161247
CAS No.: 2641482-08-6
Target:
Research Areas:
5HT2A antagonist 2 is an orally active, selective antagonist for 5HT2A with IC50 of 14 nM. 5-HT2A antagonist 2 exhibits good chemical, hepatocyte, and plasma stability, without significant cytotoxicity in cell lines VERO, HFL-1, L929, NIH3T3, CHO-K1 .
Cat. No.: HY-U00461
CAS No.: 2102501-84-6
Synonyms: Ketohexokinase inhibitor 1
Target:
Research Areas:
PF-06835919 (Ketohexokinase inhibitor 1) is a ketohexokinase (KHK) inhibitor, with IC50 values of 0.028 μM and 0.17 μM against human KHK-C and KHK-A, respectively, and an IC50 value of 0.21 μM against rat KHK. PF-06835919 blocks fructose (HY-N0395) phosphorylation and fructose metabolism. PF-06835919 can be used for research on metabolic dysfunction-associated steatotic liver disease, type 2 diabetes, hereditary fructose intolerance, and related conditions .
Cat. No.: HY-135174
CAS No.: 13081-14-6
Synonyms: L-CySSG; CYSH-GSH
Research Areas:
L-Cysteine-glutathione disulfide (L-CySSG; CYSH-GSH) is a thiol-modified glutathione prodrug with antioxidant, anti-inflammatory, and oral activities. L-Cysteine-glutathione disulfide reduces the production of mitochondrial ROS, and alleviates oxidative stress, inflammatory responses, and elevated levels of hepatic enzymes. L-Cysteine-glutathione disulfide prevents liver injury in mice induced by high-fat diet or LPS. The expression level of L-Cysteine-glutathione disulfide changes during tuberculosis infection, so it can serve as a biomarker for pulmonary tuberculosis. L-Cysteine-glutathione disulfide is applicable to research on pulmonary tuberculosis, metabolic dysfunction-associated steatotic liver disease, and liver injury .
Cat. No.: HY-156065
CAS No.: 2700303-28-0
Research Areas:
S217879 is an orally active and selective NRF2 activator. S217879 activates the NRF2 pathway by specifically disrupting the KEAP1 (Kd: 4.15 nM)-NRF2 interaction, and upregulates the antioxidant response. S217879 also ameliorates steatohepatitis and reduces the degree of liver fibrosis. S217879 can be used in the research of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis .
Cat. No.: HY-179278
Target:
Research Areas:
LXR agonist 4 is a selective LXR inverse agonist with IC50 values of 7.6 (LXRα) and 2.9 μM (LXRβ), respectively. LXR agonist 4 exhibits selectivity over RORα and FXR. LXR agonist 4 robustly suppresses SREBP1c expression without altering ABCA1 or APOE. LXR agonist 4 displays antilipogenic properties and resolves fatty acid-induced steatosis. LXR agonist 4 can be used for the research of atherosclerosis and metabolic dysfunction-associated steatotic liver disease (MASLD) .
Cat. No.: HY-173599
Target:
Research Areas:
NUV-244 is a molecular glue degrader of PNPLA3 I148M. NUV-244 induces degradation via the ubiquitin-proteasome system involving the E3 ligase BFAR. NUV-244 promotes 26S proteasome-dependent degradation of PNPLA3 I148M. NUV-244 restores lipid droplet morphology and cellular fitness in hepatocytes expressing PNPLA3 I148M. NUV-244 can be used in the research of metabolic dysfunction-associated fatty liver disease .
Cat. No.: HY-181564
CAS No.: 3115123-06-0
Target:
Research Areas:
MGAT2-IN-7 is an orally active monoacylglycerol acyltransferase 2 (MGAT2) inhibitor. MGAT2-IN-7 is used for research on obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) .
Cat. No.: HY-183723
Research Areas:
GAA-4OH is a potent and irreversible dihydroceramide desaturase-1 (DES1) inhibitor with an IC50 of 0.6 μM and a Ki of 139.5 nM. GAA-4OH undergoes oxidation to form a reactive iminoquinone that covalently blocks DES1’s catalytic cavity, causing permanent enzyme inactivation. GAA-4OH modulates sphingolipid balance by reducing ceramide-to-dihydroceramide ratios in liver tissue. GAA-4OH improves liver steatosis, inflammation, fibrosis, and reduces pro-inflammatory and pro-fibrogenic gene expression. GAA-4OH can be used for the research of metabolic dysfunction-associated steatotic liver disease (MASLD) .
Cat. No.: HY-N0732R
CAS No.: 37905-08-1
Cat. No.: HY-181862
Target:
Research Areas:
SHK1112218 is an orally active mitochondrial proton carrier with an EC50 of 0.48 μM. SHK1112218 restores proton transport and increases oxygen consumption rate. SHK1112218 can be used for the research of diabetes, obesity, and metabolic dysfunction-associated steatotic liver disease .
Cat. No.: HY-180921
CAS No.: 2845278-33-1
Target:
Research Areas:
GS-1291269 is a potent and neutral ketohexokinase (KHK) inhibitor, with IC50s of 0.38 and 2.1 nM against KHK-C and KHK-A, respectively. GS-1291269 demonstrates liver and kidney fructose-1-phosphate (F1P) reduction in a fructose challenge model in rats. GS-1291269 can be used for kidney disease and metabolic-dysfunction-associated steatotic liver disease (MASLD) research .
Cat. No.: HY-153149
CAS No.: 945457-84-1
Synonyms: FM101
Research Areas:
LJ-2698 (FM101) is an orally active adenosine A3 receptor (Adenosine A3 Receptor) antagonist . LJ-2698 blocks adenosine A3 receptor-dependent pro-inflammatory JNK, ERK, and NF-κB signaling pathways. LJ-2698 prevents alveolar cavity enlargement, restores pulmonary function, and inhibits matrix metalloproteinase activity and pulmonary cell apoptosis (apoptosis) in mice . LJ-2698 induces mitochondrial dysfunction, necroptosis, and intrinsic apoptosis. LJ-2698 ameliorates renal injury in mice with diabetic nephropathy, and alleviates diet-induced hepatic inflammation and fibrosis. LJ-2698 can be used in the research of emphysema, diabetic nephropathy, and metabolic dysfunction-associated steatotic liver disease .
Cat. No.: HY-182046
CAS No.: 2930131-74-9
Research Areas:
HD202A is an orally active, selective dual inhibitor of MNK1/MNK2 (with IC50 values of 6.09 nM and 8.06 nM, and Kd values of 1.913 μM and 5.244 μM, respectively) that inhibits the MNK-eIF4E signaling pathway. By downregulating perilipin 2 and SCD1, while upregulating adipose triglyceride lipase and PPARγ coactivator 1α, HD202A enhances mitochondrial fatty acid oxidation and redox homeostasis. HD202A effectively suppresses body weight gain, hepatic lipid accumulation and elevation of serum lipids, significantly improves glucose tolerance and insulin sensitivity of the organism, and ameliorates inflammatory features. With these comprehensive pharmacological activities, HD202A exhibits great application potential in studies of metabolic dysfunction-associated steatotic liver disease .
Cat. No.: HY-171881
CAS No.: 864686-48-6
Research Areas:
BI-5521 is an orally active GSK-3 inhibitor with an IC50 of 1.1 nM against GSK-3β. BI-5521 targets the two GSK-3 isoforms with similar potency and exhibits potent inhibitory activity against DYRK1A. By modulating GSK-3 activity, BI-5521 inhibits tumor proliferation and cancer cell growth, exerts cytotoxic effects, and reduces cancer cell viability. It shows consistent chemosensitivity across all subtypes of rhabdomyosarcoma, produces synergistic growth inhibitory effects when combined with SOS1 inhibitors, reduces oral glucose levels, regulates the myofibroblast differentiation pathway, decreases the nuclear localization of YAP/SMAD2/3, and lowers the positive rate of α-SMA in fibroblasts without affecting the apoptosis of CD4 + T cells. BI-5521 can be used in the research of non-small cell lung cancer, pleomorphic rhabdomyosarcoma, type 2 diabetes, pancreatic ductal adenocarcinoma, Alzheimer's disease, bipolar disorder, and metabolic dysfunction-associated steatotic liver disease .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
